Implementing antibody-drug conjugates (ADCs) in HER2+ BCOngoing challenges with ADCs include improving target specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection.
ONCY has been addressing the above challenges through pelareorep's clinical development plan that includes the AWARE-1 WOO study.